

IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO**Publication number:** HU0104424**Publication date:** 2002-03-28**Inventor:** CEVC GREGOR (DE)**Applicant:** IDEA AG (DE)**Classification:**

- international: A61K9/10; A61K9/127; A61K31/16; A61K31/56;
A61K31/58; A61K47/02; A61K47/10; A61K47/12;
A61K47/14; A61K47/18; A61K47/20; A61K47/22;
A61K47/24; A61K47/26; A61K47/28; A61K47/32;
A61K47/34; A61K47/36; A61K47/38; A61K47/42;
A61K47/46; A61P1/16; A61P1/18; A61P7/06;
A61P11/06; A61P13/12; A61P17/00; A61P17/06;
A61P17/14; A61P19/00; A61P19/02; A61P21/00;
A61P25/08; A61P27/00; A61P27/02; A61P29/00;
A61P31/12; A61P31/22; A61K9/10; A61K9/127;
A61K31/16; A61K31/56; A61K31/58; A61K47/02;
A61K47/10; A61K47/12; A61K47/14; A61K47/16;
A61K47/20; A61K47/22; A61K47/24; A61K47/26;
A61K47/28; A61K47/32; A61K47/34; A61K47/36;
A61K47/38; A61K47/42; A61K47/46; A61P1/00;
A61P7/00; A61P11/00; A61P13/00; A61P17/00;
A61P19/00; A61P21/00; A61P25/00; A61P27/00;
A61P29/00; A61P31/00; (IPC1-7): A61K9/127

- European: A61K9/127B2; A61K31/16; A61K31/57L5;
A61K31/57LS; A61K31/57L5L5; A61K31/58

Application number: HU20010004424 19981223**Priority number(s):** WO1998EP08421 19981223**Also published as:**

WO0038653 (A1)
EP1140021 (A1)
US7175850 (B2)
US2007184114 (A1)
US2002064524 (A1)

[more >>](#)[Report a data error here](#)

Abstract not available for HU0104424

Abstract of corresponding document: **WO0038653**

A formulation comprising molecular arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of said pores is smaller than the average penetrant diameter, provided that the penetrants can transport agents or else enable agent permeation through the pores after penetrants have entered pores, characterised in that the formulation comprises at least one consistency builder in an amount that increases the formulation to maximally 5 N/m² so that spreading over, and retention at, the application area is enabled and/or at least one antioxidant in an amount that reduces the increase of oxidation index to less than 100 % per 6 months and/or at least one microbicide in an amount that reduces the bacterial count of 1 million germs added per g of total mass of the formulation to less than 100 in the case of aerobic bacteria, to less than 10 in the case of enterobacteria, and to less than 1 in the case of Pseudomonas aeruginosa or Staphylococcus aureus, after a period of 4 days.